 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 July 1999 | Volume 131 Issue 2 | Pages 88-95
Background: Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth.
Objective: To determine the response of gastric MALT lymphoma to antibiotic treatment.
Design: Prospective, uncontrolled treatment trial.
Setting: University hospital referral center and three collaborating university and community hospitals.
Patients: 34 patients with stage I or stage II N1 gastric MALT lymphoma.
Intervention: Two of three oral antibiotic regimens—1] amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2) tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracycline, 500 mg four times daily, and metronidazole, 500 mg three times daily—were administered sequentially (usually in the order written) for 21 days at baseline and at 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate.
Measurements: Complete remission was defined as the absence of histopathologic evidence of lymphoma on endoscopic biopsy. Partial remission was defined as a reduction in endoscopic tumor stage or 50% reduction in the size of large tumors.
Results: 34 patients were followed for a mean (±SD) of 41 ± 16 months (range, 18 to 70 months) after antibiotic treatment. Of 28 H. pylori-positive patients, 14 (50% [95% CI, 31% to 69%]) achieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of the 8), and 10 (36% [CI, 19% to 56%]) did not respond to treatment. Treatment failed in all 6 (100% [CI, 54% to 100%]) H. pylori-negative patients. Patients with endoscopic appearance of gastritis (stage I T1 disease) were most likely to achieve complete remission within 18 months. Tumors in the distal stomach were associated with more favorable response than tumors in the proximal stomach.
Conclusions: A subset of H. pylori-positive gastric MALT lymphomas, including infiltrative tumors, may respond to antibiotics. The likelihood of early complete remission seems to be greatest for superficial and distal tumors.
Author and Article Information
From The University of Texas, M.D. Anderson Cancer Center, and Houston Veterans Affairs Medical Center, Houston, Texas.
Grant Support: By National Cancer Institute grant RO1 CA67540-0 2 and Cancer Center Support grant CA-16672.
Requests for Reprints: Gideon Steinbach, MD, PhD, Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas, M.D. Anderson Cancer Center, Box 78, 1515 Holcombe Boulevard, Houston, TX 77030; e-mail, gsteinb{at}aol.com.
Current Author Addresses: Drs. Steinbach, Ford, Glober, Hagemeister, Lynch, McLaughlin, Rodriguez, Romaguera, Sarris, Younes, Luthra, Manning, Lahoti, Shen, Lee, Winn, and Cabanillas, Ms. Sample, and Ms. Johnson: The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Drs. Genta and Graham: Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030. ARTICLE
Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial
This article has been cited by other articles:
|
|
 |
|
  P. G. Gobbi, F. Corbella, F. Valentino, M. Bergonzi, C. Sangalli, V. Perfetti, and G. R. Corazza Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy Ann. Onc., December 11, 2008; (2008) mdn668v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Bacon, M.-Q. Du, and A. Dogan Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists J. Clin. Pathol., April 1, 2007; 60(4): 361 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Cohen, M. Petryk, M. Varma, P. S. Kozuch, E. D. Ames, and M. L. Grossbard Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue Oncologist, November 1, 2006; 11(10): 1100 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Ha, L. J. Medeiros, C. Charnsangavej, M. Crump, and M. K. Gospodarowicz Oncodiagnosis Panel: 2004: Lymphoma RadioGraphics, March 1, 2006; 26(2): 607 - 620. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Francois and M. J. Blaser Improving Helicobacter pylori Eradication Regimens Ann Intern Med, January 17, 2006; 144(2): 140 - 141. [Full Text] [PDF]
|
|
|
|
 |
|
 L.-T. Chen, J.-T. Lin, J. J. Tai, G.-H. Chen, H.-Z. Yeh, S.-S. Yang, H.-P. Wang, S.-H. Kuo, B.-S. Sheu, C.-M. Jan, et al. Long-Term Results of Anti-Helicobacter pylori Therapy in Early-Stage Gastric High-Grade Transformed MALT Lymphoma J Natl Cancer Inst, September 21, 2005; 97(18): 1345 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bertoni and E. Zucca State-of-the-Art Therapeutics: Marginal-Zone Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6415 - 6420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Montalban, A. Santon, C. Redondo, M. Garcia-Cosio, D. Boixeda, E. Vazquez-Sequeiros, F. Norman, C. M. de Argila, I. Alvarez, V. Abraira, et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study Ann. Onc., September 1, 2005; 16(9): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Martinelli, D. Laszlo, A. J.M. Ferreri, G. Pruneri, M. Ponzoni, A. Conconi, C. Crosta, E. Pedrinis, F. Bertoni, L. Calabrese, et al. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy J. Clin. Oncol., March 20, 2005; 23(9): 1979 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Fischbach, M-E Goebeler-Kolve, B Dragosics, A Greiner, and M Stolte Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series Gut, January 1, 2004; 53(1): 34 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Aljurf, T. W. Owaidah, A. Ezzat, E. Ibrahim, and A. Tbakhi Antigen- and/or immune-driven lymphoproliferative disorders Ann. Onc., November 1, 2003; 14(11): 1595 - 1606. [Full Text] [PDF]
|
|
|
|
|
|
R Sinharay Long term follow up of Helicobacter pylori induced gastric diffuse large B cell MALT lymphoma following eradication treatment alone Gut, September 1, 2003; 52(9): 1385 - 1385. [Full Text]
|
|
|
|
|
|
A Ruskone-Fourmestraux, B Dragosics, A Morgner, A Wotherspoon, and D de Jong Paris staging system for primary gastrointestinal lymphomas Gut, June 1, 2003; 52(6): 912 - 913. [Full Text]
|
|
|
|
|
|
M M Alsolaiman, G Bakis, T Nazeer, R P MacDermott, and J A Balint Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection Gut, April 1, 2003; 52(4): 507 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Stolte, E Bayerdorffer, A Morgner, B Alpen, T Wundisch, C Thiede, and A Neubauer Helicobacter and gastric MALT lymphoma Gut, May 1, 2002; 50(90003): iii19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-T. Chen, J.-T. Lin, R.-Y. Shyu, C.-M. Jan, C.-L. Chen, I-P. Chiang, S.-M. Liu, I.-J. Su, and A.-L. Cheng Prospective Study of Helicobacter pylori Eradication Therapy in Stage IE High-Grade Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach J. Clin. Oncol., November 15, 2001; 19(22): 4245 - 4251. [Abstract] [Full Text]
|
|
|
|
|
|
C Montalban, A Santon, D Boixeda, and C Bellas Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication Gut, October 1, 2001; 49(4): 584 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A MORGNER, E BAYERDORFFER, A NEUBAUER, and M STOLTE Helicobacter pylori associated gastric B cell MALT lymphoma: predictive factors for regression Gut, March 1, 2001; 48(3): 290 - 292. [Full Text] [PDF]
|
|
|
|
|
|
A Ruskone-Fourmestraux, A Lavergne, P H Aegerter, F Megraud, L Palazzo, A de Mascarel, T Molina, and J-C L Rambaud Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment Gut, March 1, 2001; 48(3): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cavalli, P. G. Isaacson, R. D. Gascoyne, and E. Zucca MALT Lymphomas Hematology, January 1, 2001; 2001(1): 241 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Greenberger Update in Gastroenterology Ann Intern Med, October 3, 2000; 133(7): 542 - 548. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zucca, F. Bertoni, E. Roggero, and F. Cavalli The gastric marginal zone B-cell lymphoma of MALT type Blood, July 15, 2000; 96(2): 410 - 419. [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Peterson, A. M. Fendrick, D. R. Cave, D. A. Peura, S. M. Garabedian-Ruffalo, and L. Laine Helicobacter pylori-Related Disease: Guidelines for Testing and Treatment Arch Intern Med, May 8, 2000; 160(9): 1285 - 1291. [Abstract] [Full Text] [PDF]
|
|
Article
